Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Senores Pharmaceuticals Ltd. (SENORES.NS)
Ahmedabad, IN
Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches markets across India, the United States, the United Kingdom, Canada, and other international territories. The company specializes in a diverse array of therapeutic solutions, encompassing analgesics/antipyretics, anesthetics, antibacterials, antivirals, antifungals, antioxidants, antineoplastics, blood-related therapies, cardiovascular and neurological medications, antacids, and vitamin and mineral supplements. Additionally, Senores offers a selection of generic drugs targeting pain, inflammation, fever, diabetes, malaria, and urinary tract conditions, as well as neutral supplements. Complementing its product offerings, the firm also provides management and consultancy services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.33% | +7.74% | +26.05% | +42.62% | +40.14% | +35.45% | +120.57% | +99.80% | +99.80% | +99.80% | +99.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+65.3% ★ Q1'26: +77.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+13,789.5% ★
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-3.2% Q1'26: -41.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+29.1% ★ Q1'26: +31.9% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+14.4% ★ Q1'26: +17.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+20.2%
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.59× Q1'26: 1.31× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 3 EPS Ana. |
Mar 2028 4 Rev. Ana. 3 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
3.83B
est: 4.46B (-14.2%)
|
6.45B
6.19B – 6.67B
+44.6% YoY
|
8.29B
7.98B – 8.60B
+28.5% YoY
|
10.47B
9.10B – 11.61B
+26.3% YoY
|
12.33B
11.22B – 13.30B
+17.8% YoY
|
| EBITDA |
1.08B
est: 1.39B (-22.3%)
|
2.01B
1.93B – 2.08B
+44.6% YoY
|
2.58B
2.48B – 2.67B
+28.5% YoY
|
3.26B
2.83B – 3.61B
+26.3% YoY
|
3.84B
3.49B – 4.14B
+17.8% YoY
|
| EBIT |
909.40M
est: 1.18B (-22.9%)
|
1.71B
1.64B – 1.76B
+44.6% YoY
|
2.19B
2.11B – 2.27B
+28.5% YoY
|
2.77B
2.40B – 3.07B
+26.3% YoY
|
3.26B
2.96B – 3.51B
+17.8% YoY
|
| Net Income |
6.85M
est: 454.70M (-98.5%)
|
982.66M
867.45M – 1.10B
+116.1% YoY
|
1.54B
1.31B – 1.63B
+56.6% YoY
|
2.07B
1.69B – 2.22B
+34.4% YoY
|
2.51B
1.95B – 2.82B
+21.4% YoY
|
| SGA |
157.30M
est: 91.68M (+71.6%)
|
132.56M
127.24M – 137.09M
+44.6% YoY
|
170.34M
164.05M – 176.62M
+28.5% YoY
|
215.08M
186.94M – 238.55M
+26.3% YoY
|
253.39M
230.48M – 273.19M
+17.8% YoY
|
| EPS |
0.19
est: 10.40 (-98.2%)
|
22.98
19.84 – 25.11
+120.9% YoY
|
33.00
30.00 – 37.30
+43.6% YoY
|
42.90
38.55 – 50.68
+30.0% YoY
|
54.50
44.60 – 64.40
+27.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck India Growth Leaders ETF GLIN | 0.15% | 152.0K | 0.72% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 141.6K | 0.65% |
| 3 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.01% | 30.6K | 0.33% |
| 4 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 1.02M | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Swapnil Jatinbhai Shah | MD & Director | 30M | male |
| Chetan Bipinchandra Shah | Whole-Time Director & Chief Operating Officer | 12M | male |
| Deval Rajnikant Shah | Whole-Time Director & Chief Financial Officer | 11M | male |
| Jignesh Shashikant Desai | President of Finance | — | male |
| Manohar Lalge | President of Research & Development | — | male |
| Vinay Kumar Mishra | Company Secretary & Compliance Officer | — | male |
| Deepak Jain | Vice President of Regulatory Affairs | — | male |
| Hanuwant Singh Shaktawat | Assistant Vice President of HR & Admin | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SENORES.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
